DUE DILIGENCE PROJECTS, FIRST-IN-HUMAN/FIRST-IN-PLATFORM CLINICAL TRIALS DESIGN AND CONDUCT, FRACTIONAL CMO SUPPORT
Leverage Our Expertise to Your Specific Needs
Expert strategic and tactical services for: early drug development in oncology, rare diseases, gene editing and complicated clinical pharmacology challenges.
ONCOLOGY SERVICES
We bring special expertise in First-in-Human and First-in-Platform Phase 1 studies. We can provide limited services focused on the dose escalation plan or extensive services including fractional CMO overseeing development of IND, Protocol, CRO and site selection, and efficient execution of dose escalation decisions and study completion.
GENE EDITING SERVICES
We can capably bring the same options to your rare disease- or oncology-oriented gene editing projects.
DUE DILIGENCE AND STRATEGIC ASSESSMENTS
Short term research and evaluation projects for start-up Biotechs and Venture Capital firms to evaluate entity acquisitions or revise portfolios.
